SCHEMBL26529342

SCHEMBL26529342

CC(C)c1ccc(-c2cccn2C)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PCSK9 Q8NBP7 1/20 0.47
ALDH1A1 P00352 2/20 0.46
CYP2A6 P11509 1/20 0.46
CYP2A13 Q16696 1/20 0.46
SLC6A3 Q01959 1/20 0.40
MAPT P10636 3/20 0.35
GAA P10253 2/20 0.35
TP53 P04637 2/20 0.35
KDM4E B2RXH2 3/20 0.35
NPC1 O15118 3/20 0.34
RAB9A P51151 3/20 0.34
NOTUM Q6P988 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
MEN1 O00255 2/20 0.34
LMNA P02545 2/20 0.34
KMT2A Q03164 2/20 0.34
PAX8 Q06710 1/20 0.34
NOD2 Q9HC29 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
RECQL P46063 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18999650 0.82 PCSK9 (0.46) PCSK9ALDH1A1CYP2A6CYP2A13SLC6A3
SCHEMBL11357896 0.79 PCSK9 (0.50) PCSK9ALDH1A1CYP2A6CYP2A13SLC6A3
SCHEMBL3188837 0.79 PCSK9 (0.50) PCSK9ALDH1A1CYP2A6CYP2A13SLC6A3
SCHEMBL19029343 0.78 MAPT (0.37) MAPTTP53KDM4ENPC1RAB9A
SCHEMBL28310880 0.77 PCSK9 (0.52) PCSK9ALDH1A1CYP2A6CYP2A13SLC6A3
SCHEMBL22607376 0.77 ALDH1A1 (0.40) PCSK9ALDH1A1CYP2A6CYP2A13SLC6A3
SCHEMBL6444709 0.76 PCSK9 (0.73) PCSK9ALDH1A1CYP2A6CYP2A13SLC6A3
SCHEMBL11359663 0.75 PCSK9 (0.50) PCSK9ALDH1A1CYP2A6CYP2A13SLC6A3
SCHEMBL10446086 0.74 AHR (0.48) PCSK9ALDH1A1CYP2A6CYP2A13MAPT
SCHEMBL24992270 0.73 ALDH1A1 (0.37) PCSK9ALDH1A1CYP2A6CYP2A13SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873295-B2 Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease PETRA PHARMA CORPORATION (US) 2024-01-16 US disclosed
US-20230322747-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF EIKONIZO THERAPEUTICS, INC. (US) 2023-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322747-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF HDAC6, HDAC1, HDAC11 PCSK9 3991/4885ALDH1A1 755/4885CYP2A6 4456/4885
US-11873295-B2 Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease PIK3CA, PIK3R4, PIK3R5 PCSK9 801/4885ALDH1A1 3412/4885CYP2A6 833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.